Clinical trial reportInflammatory bowel diseasesPublished
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Inflammatory bowel diseases
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Crohn Disease; Treatment Outcome; Remission Induction; Severity of Illness Index; Follow-Up Studies; Adult; Middle Aged; Female; Male; Young Adult; Antibodies, Monoclonal, Humanized
- PubMed ID
- 42065683
- PubMed Central ID
- PMC13533210
- Open access
- Yes, open
- Added to directory
- Source checked